Hypertension, Pulmonary
Conditions
Keywords
propofol, isoflurane, pulmonary hypertension, congenital heart disease
Brief summary
The investigators hypothesize that there is no difference between the effects of isoflurane and propofol anaesthesia on pulmonary vascular resistance (PVR).
Interventions
both drugs administered at age-related dose and titrated to effect. maximum dose of propofol 15 mg/kg/hr, maximum dose of isoflurane 1.5 MAC
Sponsors
University Hospitals Bristol and Weston NHS Foundation Trust
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
3 Months to 16 Years
Healthy volunteers
No
Inclusion criteria
* All children between 3 months and 16 years of age with pulmonary arterial hypertension undergoing a PVR study.
Exclusion criteria
* Children with a known adverse reaction to one of the study drugs eg malignant hyperpyrexia or a disorder of fatty acid oxidation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the percentage change in PVR under isoflurane anaesthesia compared with propofol anaesthesia. | 2 hours |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints are the percentage change in mean pulomanry artery pressure (PAP), systemic vascular resistance (SVR) and mean arterial pressure (MAP). | 2 hours |
Countries
United Kingdom
Outcome results
None listed